-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications using multiomics -- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost -- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027 -- Illumina and the Broad Institute of MIT and Harvard announce new research partnership to advance single-cell sequencing SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today is hosting a Strategy Update for investors to present its strategy and three-year financial outlook that features accelerating revenue growth and significant margin expansion.
"Illumina built the foundation of the genomics industry, and we will continue leading innovation across total sequencing workflows to support the next phase of our customers' success," said Jacob Thaysen , Chief Executive Officer of Illumina. "Over the next three years, we will bring to market impressive new innovations that will redefine the genome and drive significant, deeper biological insights through multiomics." Today, Illumina and the Broad Institute of MIT and Harvard are also announcing a new research partnership to advance single-cell sequencing and accelerate adoption of high-capacity single-cell experiments, leveraging Illumina's Fluent technology.
As part of .